Werewolf Therapeutics reports Q2 EPS (14c), consensus (42c)

Reports Q2 revenue $8.1M, consensus $2.46M. “Throughout the second quarter, we have continued advancing our INDUKINE pipeline with ongoing enrollment of our first-in-human clinical trials for WTX-124 and WTX-330, our two lead programs,” said Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf. “We look towards the fourth quarter, when we anticipate sharing initial safety, tolerability, pharmacokinetics and biomarker data from our Phase 1/1b trial of WTX-124 in multiple solid tumors. Additionally, we are pleased that Jazz Pharmaceuticals has announced the Investigational New Drug application clearance of JZP898, an engineered IFNalpha INDUKINE molecule. Werewolf continues to operate from a position of financial strength with a cash runway projected to carry us through at least the fourth quarter of 2024.”